Chammas & Marcheteau

We are only able to display limited information for this firm. We display more complete information for all of the following firms:

Chammas & Marcheteau advises on venture and growth capital transactions both across France and on cross-border deals. Leadership is shared between Lola Chammas , Denis Marcheteau  and Nicolas Lecocq. Chammas advises on fund structuring, M&A and private equity transactions in the tech, energy and pharmaceuticals sectors. Marcheteau brings expertise to acquisitions, divestments, capital raises and governance matters, most notably in the mobility, life sciences and finance industries, and Lecocq represents French companies and funds in their investment and divestment transactions, notably in the software, healthcare, Medtech, biotech, education and cleantech sectors.
Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘The Chammas & Marcheteau team stands out for its ability to combine rigorous legal expertise with a strategic, business-oriented vision. Their advice is always pragmatic and actionable, which clearly differentiates them from the more theoretical approaches of some competitors. The constant involvement and availability of the partners and senior lawyers guarantees excellent quality. Since the fundraising round we completed with them, they have been a key partner.’
  • ‘Denis Marcheteau, whose strategic vision and poise in the complex negotiations we have undertaken are outstanding. He is remarkably supported by Jérôme Chapon and Jérémie Lolmède, who are the true driving force behind our cases on a daily basis thanks to their technical rigour and exceptional responsiveness. What sets them apart is their perfect complementarity, one provides the strategic direction, the others ensure flawless and reliable execution. This makes the team remarkably effective.’

Key clients

  • Supernova Invest
  • NetZero

Work highlights

Advised Supernova Invest on its entry into the capital of Expliseat as part of a €36 million fundraising round.